© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $232.00. The company’s shares closed yesterday at $229.51. Zimmerman covers ...
Truist Financial analyst Richard Newitter maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback